FDA Approves Bayer’s KOVALTRY® Antihemophilic Factor (Recombinant) for the Treatment of Children and Adults with Hemophilia A
Whippany, NJ, March 17, 2016 – The U.S. Food and Drug Administration has approved Bayer’s KOVALTRY® Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on results from the LEOPOLD (Long-Term